NVCR Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Novocure Ltd (NVCR) is not a strong buy at the moment for a beginner investor with a long-term strategy. The stock shows mixed signals with no strong positive catalysts, weak financial performance, and neutral trading sentiment. While the technical indicators suggest some short-term upward momentum, the lack of significant growth drivers and a declining financial trend make it prudent to hold off on buying this stock.
The MACD is positive and expanding, indicating short-term bullish momentum. The RSI is neutral at 78.958, and moving averages are converging, showing no strong directional trend. The stock is trading near its resistance level (R1: 12.301), which may act as a barrier for further upward movement.
FDA approval of Optune Pax for pancreatic cancer treatment earlier in the year, which led to a raised price target by H.C. Wainwright.
Declining financial performance in Q4 2025, including a significant drop in net income (-62.84% YoY) and EPS (-63.93% YoY). Analysts have also lowered price targets, with Evercore ISI reducing the target to $16.
In Q4 2025, revenue increased by 8.11% YoY to $174.35M, but net income dropped significantly to -$24.5M (-62.84% YoY), and EPS fell to -0.22 (-63.93% YoY). Gross margin also declined to 75.82% (-4.33% YoY), indicating weakening profitability.
Analysts are mixed. Evercore ISI recently lowered the price target to $16 but maintained an Outperform rating. H.C. Wainwright raised the price target to $47 earlier in the year following FDA approval of a new treatment.
